These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer.
No takes yet. Share an insight, caveat, or question.
Theriault et al. (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: